Next Article in Journal
Microbiological Evaluation of 5 L- and 20 L-Transparent Polypropylene Buckets for Solar Water Disinfection (SODIS)
Next Article in Special Issue
PPARs as Nuclear Receptors for Nutrient and Energy Metabolism
Previous Article in Journal
In Vitro Human Metabolism and Inhibition Potency of Verbascoside for CYP Enzymes
Previous Article in Special Issue
Clofibrate Treatment Decreases Inflammation and Reverses Myocardial Infarction-Induced Remodelation in a Rodent Experimental Model
Open AccessArticle

The PPARγ Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth through an Immune-Mediated Mechanism

1
Department of Pathology & Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
2
Department of Dermatology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
3
Richard L. Roudebush VA Medical Center, Indianapolis, IN 46202, USA
4
Currently in the Department of Pathology, University of Missouri-Kansas City, Kansas City, MO 64108, USA
5
Department of Pharmacology & Toxicology, Wright State University, Dayton, OH 45435, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Raffaele Capasso and Fabio Arturo Iannotti
Molecules 2019, 24(11), 2192; https://doi.org/10.3390/molecules24112192
Received: 16 May 2019 / Revised: 7 June 2019 / Accepted: 8 June 2019 / Published: 11 June 2019
(This article belongs to the Special Issue Role of PPAR Receptors in Human Health and Disease)
Recent evidence suggests that PPARγ agonists may promote anti-tumor immunity. We show that immunogenic PDV cutaneous squamous cell carcinoma (CSCC) tumors are rejected when injected intradermally at a low cell number (1 × 106) into immune competent syngeneic hosts, but not immune deficient mice. At higher cell numbers (5 × 106 PDV cells), progressively growing tumors were established in 14 of 15 vehicle treated mice while treatment of mice with the PPARγ agonist rosiglitazone resulted in increased tumor rejection (5 of 14 tumors), a significant decrease in PDV tumor size, and a significant decrease in tumor cell Ki67 labeling. Rosiglitazone treatment had no effect on tumor rejection, tumor volume or PDV tumor cell proliferation in immune deficient NOD.CB17-PrkdcSCID/J mice. Rosiglitazone treatment also promoted an increase in tumor infiltrating CD3+ T-cells at both early and late time points. In contrast, rosiglitazone treatment had no significant effect on myeloid cells expressing either CD11b or Gr-1 but suppressed a late accumulation of myeloid cells expressing both CD11b and Gr-1, suggesting a potential role for CD11b+Gr-1+ myeloid cells in the late anti-tumor immune response. Overall, our data provides evidence that the PPARγ agonist rosiglitazone promotes immune-mediated anti-neoplastic activity against tumors derived from this immunogenic CSCC cell line. View Full-Text
Keywords: peroxisome proliferator activated receptor gamma; rosiglitazone; T-cells; myeloid cells; anti-tumor immunity peroxisome proliferator activated receptor gamma; rosiglitazone; T-cells; myeloid cells; anti-tumor immunity
Show Figures

Figure 1

MDPI and ACS Style

Konger, R.L.; Derr-Yellin, E.; Ermatov, N.; Ren, L.; Sahu, R.P. The PPARγ Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth through an Immune-Mediated Mechanism. Molecules 2019, 24, 2192.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop